<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="in severity, ranging from asymptomatic carriage to mild respiratory tract" exact="infection" post="and severe or fatal pneumonia. Moreover, SARS-CoV-2 can be"/>
 <result pre="(Alphacoronavirus) and HKU1 (Betacoronavirus) that often cause mild respiratory tract" exact="infection" post="as well as SARS-CoV and MERS-CoV that in contrast"/>
 <result pre="in vitro antiviral activity and preliminary clinical experiences in the" exact="treatment" post="of COVID-19. 2 Mode of action of remdesivir: a"/>
 <result pre="anywhere so far. Moreover, GS-441524 has been recommended for the" exact="treatment" post="of cats with feline infectious peritonitis, which is uncommon"/>
 <result pre="evident decline in pulmonary viral loads by 4 days after" exact="infection" post="than wild-type SARS-CoV-infected mice, indicative of attenuated pathogenicity of"/>
 <result pre="and further encourage the therapeutic potential of remdesivir in the" exact="treatment" post="of newly emerging COVID-19. 4 Clinical efficacy and tolerance"/>
 <result pre="Ebola virus and protected all infected animals against this lethal" exact="infection" post="[15]. Besides, in a mouse model of SARS-CoV infection,"/>
 <result pre="from Scotland with Ebola meningoencephalitis, which was supported by the" exact="detection" post="of Ebola virus RNA in plasma and cerebrospinal fluid,"/>
 <result pre="plasma and cerebrospinal fluid, its first use for Ebola virus" exact="infection" post="in humans, was reported in 2016 [22]. She was"/>
 <result pre="adverse effects were observed. Of note, real-time reverse transcription PCR" exact="testing" post="for SARS-CoV-2 in nasopharyngeal and oropharyngeal swabs remained positive"/>
 <result pre="is 308 and 452, respectively. A 10-day regimen of remdesivir" exact="treatment" post="is as follows: 200 mg loading dose on Day"/>
 <result pre="Two randomised clinical trials of parenteral remdesivir therapy in the" exact="treatment" post="of COVID-19 in China may open the window for"/>
 <result pre="Feb 1510592310.1016/j.ijantimicag.2020.105923 11LiuW.MorseJ.S.LalondeT.XuS.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoVChembiochem21202073073810.1002/cbic.20200004732022370"/>
 <result pre="prodrug of a pyrrolo[2,1-f] [triazin-4-amino] adenine c-nucleoside (GS-5734) for the" exact="treatment" post="of Ebola and emerging virusesJ Med Chem6020171648166110.1021/acs.jmedchem.6b0159428124907 14PedersenN.C.PerronM.BannaschM.MontgomeryE.MurakamiE.LiepnieksM.Efficacy and"/>
 <result pre="Chem6020171648166110.1021/acs.jmedchem.6b0159428124907 14PedersenN.C.PerronM.BannaschM.MontgomeryE.MurakamiE.LiepnieksM.Efficacy and safety of the nucleoside analog GS-441524 for" exact="treatment" post="of cats with naturally occurring feline infectious peritonitisJ Feline"/>
</results>
